Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Manistee Therapeutics78 enrolled

Overview

The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101. The main questions it aims to answer are: Does the drug MTX101 lower headache pain for participants and the need to use a rescue medication? What side effects, if any, do participants have when taking the drug MTX101? Researchers will compare the drug MTX101 to a placebo (a look-alike substance that contains no drug) to see if the drug MTX101 works to treat acute migraine attacks. Participants will: Take the drug MTX101 or a placebo to treat 1 migraine attack with each treatment. Visit the clinic twice and have one phone call over a 4 week period for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication.

Subjects enrolled in the study will be randomized to receive investigational product (MTX101 2mg or placebo), to be taken as soon as they have a migraine headache that reaches moderate to severe intensity. Subjects will take a single dose of either active or placebo to treat one migraine headache. Rescue medication should not be taken until at least 2 hours post study medication dose. The subject will have a telephone check up within 72 to 120 hours after treatment of the first migraine headache. The subject will treat a 2nd moderate to severe migraine at least 48 hours after the first treated migraine headache. The subject will return to the clinic for re-evaluation within a 4 week period from the start of the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: 1. Male or female aged 18 to 65 years at the time of consent. 2. Onset of migraine headache before age 50. 3. History of episodic migraine headache starting at least 1-year ago with or without aura. 4. Has a minimum of 4 monthly migraine days and not more than 10 migraine days per month. 5. Able to distinguish pain related to migraine attacks from tension-type and cluster headache attacks. 6. Able to understand and provide signed informed consent. 7. Willing and able to comply with all scheduled visits, treatment plan, and other study procedures. Key Exclusion Criteria: 1. No more than a total of 15 headache days per month. 2. Use of more than 2 migraine preventive medications. 3. Current diagnosis of glaucoma. 4. Use of opioids or barbiturates more than 4 days/month, triptans or ergots 10 or more days/month, or simple analgesics (e.g., aspirin, NSAIDs, acetaminophen) 15 or more days/month in the 3 months prior to Visit 1. 5. Current diagnosis of any post-traumatic headaches, medication overuse headaches, new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), painful cranial neuropathy or daily headaches. 6. Vaccination within less than 7 days from the Screening or plans to get a vaccine during the study or within a week after final study dose.

Locations (7)

Kaizen Brain Center

La Jolla, California, United States

Clinical Research Institute, LLC

Santa Monica, California, United States

Brainstorm Research

Miami, Florida, United States

Synergy Clinical Research/Emerald Coast Center for Neurological Disorders

Pensacola, Florida, United States

DelRicht Research

New Orleans, Louisiana, United States

QUEST Research Institute

Farmington Hills, Michigan, United States

Wasatch Clinical Research

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Safety assessment (occurrence of adverse events, treatment emergent adverse events and serious adverse events).

To assess the tolerability and safety of MTX101. This objective will be measured by assessing the number of unique subjects with deaths, serious adverse events, and moderate and severe adverse events.

Time frame: Treatment emergent adverse event safety assessments will be limited to the first 48 hours after a treated attack.

Secondary Outcomes

The change in migraine headache pain score, using an 11-point Numerical Rating Scale, (0=no pain, 10=worst possible pain).

This objective will be measured by change in migraine headache pain score, using an 11-point Numerical Rating Scale, (0=no pain, 10=worst possible pain), from the time of dosing (t=0 hour) to 2 hours post-dose as recorded on the subject's Diary.

Time frame: From the time of dosing (t=0 hour) to 2 hours post-dose.